Dysregulated fibroblast growth factor (FGF) signaling in neurological and psychiatric disorders

Seminars in Cell and Developmental Biology

Volumn 53, Issue , 2016, Pages 136-143

  Turner, Cortney A ^a   Eren Koçak, Emine ^b   Inui, Edny G ^c   Watson, Stanley J ^a,d   Akil, Huda ^a,d  

^a UNIVERSITY OF MICHIGAN   (United States)

^b HACETTEPE UNIVERSITY   (Turkey)

^c Sagient Research Systems   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Brain; Development; Hippocampus; Neurological; Psychiatric; Therapeutics

Indexed keywords

ANTIBODY; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; LIGAND; PEPTIDE; PEPTIDOMIMETIC AGENT;

DEGENERATIVE DISEASE; DEVELOPMENT; DRUG TARGETING; HUMAN; MENTAL DISEASE; MOLECULAR BIOLOGY; MOLECULAR PATHOLOGY; NEUROLOGIC DISEASE; NONHUMAN; PROTEIN FAMILY; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; METABOLISM; MOLECULARLY TARGETED THERAPY;

ANIMALS; FIBROBLAST GROWTH FACTORS; HUMANS; MENTAL DISORDERS; MOLECULAR TARGETED THERAPY; NERVOUS SYSTEM DISEASES; RECEPTORS, FIBROBLAST GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84951162073     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2015.10.003     Document Type: Review

References (97)

1. Levi-Montalcini R. The nerve growth factor 35 years later. Science 1987, 237:1154-1162.
2. Barde Y.A., Edgar D., Thoenen H. Purification of a new neurotrophic factor from mammalian brain. EMBO J. 1982, 1:549-553.
3. Thoenen H. The changing scene of neurotrophic factors. Trends Neurosci. 1991, 14:165-170.
4. Tang J.B., Chen C.H., Zhou Y.L., McKeever C., Liu P.Y. Regulatory effects of introduction of an exogenous FGF2 gene on other growth factor genes in a healing tendon. Wound Repair Regen. 2014, 22:111-118.
5. Yanagita M., Kojima Y., Kubota M., Mori K., Yamashita M., Yamada S., et al. Cooperative effects of FGF-2 and VEGF-A in periodontal ligament cells. J. Dent. Res. 2014, 93:89-95.
6. Evans S.J., Choudary P.V., Neal C.R., Li J.Z., Vawter M.P., Tomita H., et al. Dysregulation of the fibroblast growth factor system in major depression. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:15506-15511.
7. Rubenstein J.L. Annual research review: development of the cerebral cortex: implications for neurodevelopmental disorders. J. Child Psychol. Psychiatry 2011, 52:339-355.
8. Borello U., Cobos I., Long J.E., McWhirter J.R., Murre C., Rubenstein J.L. FGF15 promotes neurogenesis and opposes FGF8 function during neocortical development. Neural. Dev. 2008, 3:17.
9. Amaral D.G., Schumann C.M., Nordahl C.W. Neuroanatomy of autism. Trends Neurosci. 2008, 31:137-145.
10. Shimamura K., Rubenstein J.L. Inductive interactions direct early regionalization of the mouse forebrain. Development 1997, 124:2709-2718.
11. Mott N.N., Chung W.C., Tsai P.S., Pak T.R. Differential fibroblast growth factor 8 (FGF8)-mediated autoregulation of its cognate receptors Fgfr1 and Fgfr3, in neuronal cell lines. PLoS ONE 2010, 5:e10143.
12. Cholfin J.A., Rubenstein J.L. Patterning of frontal cortex subdivisions by Fgf17. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:7652-7657.
13. Cholfin J.A., Rubenstein J.L. Frontal cortex subdivision patterning is coordinately regulated by Fgf8 Fgf17, and Emx2. J. Comp. Neurol. 2008, 509:144-155.
14. Terauchi A., Johnson-Venkatesh E.M., Toth A.B., Javed D., Sutton M.A., Umemori H. Distinct FGFs promote differentiation of excitatory and inhibitory synapses. Nature 2010, 465:783-787.
15. Kanda T., Iwasaki T., Nakamura S., Kurokawa T., Ikeda K., Mizusawa H. Self-secretion of fibroblast growth factor-9 supports basal forebrain cholinergic neurons in an autocrine/paracrine manner. Brain Res. 2000, 876:22-30.
16. Vaccarino F.M., Schwartz M.L., Raballo R., Nilsen J., Rhee J., Zhou M., et al. Changes in cerebral cortex size are governed by fibroblast growth factor during embryogenesis. Nat. Neurosci. 1999, 2:848.
17. Nandy S.B., Mohanty S., Singh M., Behari M., Airan B. Fibroblast Growth Factor-2 alone as an efficient inducer for differentiation of human bone marrow mesenchymal stem cells into dopaminergic neurons. J. Biomed. Sci. 2014, 21:83.
18. Okada-Ban M., Thiery J.P., Jouanneau J. Fibroblast growth factor-2. Int. J. Biochem. Cell Biol. 2000, 32:263-267.
19. Cheng Y., Rodriguiz R.M., Murthy S.R., Senatorov V., Thouennon E., Cawley N.X., et al. Neurotrophic factor-alpha1 prevents stress-induced depression through enhancement of neurogenesis and is activated by rosiglitazone. Mol. Psychiatry 2015, 20:744-754.
20. Xue G., Yan H.L., Zhang Y., Hao L.Q., Zhu X.T., Mei Q., et al. c-Myc-mediated repression of miR-15-16 in hypoxia is induced by increased HIF-2alpha and promotes tumor angiogenesis and metastasis by upregulating FGF2. Oncogene 2015, 34:1393-1406.
21. Numakawa T., Nakajima S., Yamamoto N., Ooshima Y., Odaka H., Hashido K., et al. Basic fibroblast growth factor induces miR-134 upregulation in astrocyte for cell maturation. Biochem. Biophys. Res. Commun. 2015, 456:465-470.
22. Forthmann B., Grothe C., Claus P. A nuclear odyssey: fibroblast growth factor-2 (FGF-2) as a regulator of nuclear homeostasis in the nervous system. Cell. Mol. Life Sci. 2015, 72:1651-1662.
23. Zacherl S., La Venuta G., Muller H.M., Wegehingel S., Dimou E., Sehr P., et al. A direct role for ATP1A1 in unconventional secretion of fibroblast growth factor 2. J. Biol. Chem. 2015, 290:3654-3665.
24. Leng Y., Wang Z., Tsai L.K., Leeds P., Fessler E.B., Wang J., et al. FGF-21, a novel metabolic regulator, has a robust neuroprotective role and is markedly elevated in neurons by mood stabilizers. Mol. Psychiatry 2015, 20:215-223.
25. Fakhri H., Ricken R., Adli M., Fajol A., Walter M., Foller M., et al. Impact of lithium treatment on FGF-23 serum concentrations in depressive patients. J. Clin. Psychopharmacol. 2014, 34:745-747.
26. Antonellis P.J., Kharitonenkov A., Adams A.C. Physiology and endocrinology symposium: FGF21: insights into mechanism of action from preclinical studies. J. Anim. Sci. 2014, 92:407-413.
27. Liu P., Chen L., Bai X., Karaplis A., Miao D., Gu N. Impairment of spatial learning and memory in transgenic mice overexpressing human fibroblast growth factor-23. Brain Res. 2011, 1412:9-17.
28. Asai T., Wanaka A., Kato H., Masana Y., Seo M., Tohyama M. Differential expression of two members of FGF receptor gene family FGFR-1 and FGFR-2 mRNA, in the adult rat central nervous system. Brain Res. Mol. Brain Res. 1993, 17:174-178.
29. Estival A., Monzat V., Miquel K., Gaubert F., Hollande E., Korc M., et al. Differential regulation of fibroblast growth factor (FGF) receptor-1 mRNA and protein by two molecular forms of basic FGF Modulation of FGFR-1 mRNA stability. J. Biol. Chem. 1996, 271:5663-5670.
30. Peng H., Myers J., Fang X., Stachowiak E.K., Maher P.A., Martins G.G., et al. Integrative nuclear FGFR1 signaling (INFS) pathway mediates activation of the tyrosine hydroxylase gene by angiotensin II, depolarization and protein kinase C. J. Neurochem. 2002, 81:506-524.
31. Fang X., Stachowiak E.K., Dunham-Ems S.M., Klejbor I., Stachowiak M.K. Control of CREB-binding protein signaling by nuclear fibroblast growth factor receptor-1: a novel mechanism of gene regulation. J. Biol. Chem. 2005, 280:28451-28462.
32. Ohkubo Y., Uchida A.O., Shin D., Partanen J., Vaccarino F.M. Fibroblast growth factor receptor 1 is required for the proliferation of hippocampal progenitor cells and for hippocampal growth in mouse. J. Neurosci. 2004, 24:6057-6069.
33. Zhao M., Li D., Shimazu K., Zhou Y.X., Lu B., Deng C.X. Fibroblast growth factor receptor-1 is required for long-term potentiation, memory consolidation, and neurogenesis. Biol. Psychiatry 2007, 62:381-390.
34. Thomson R.E., Kind P.C., Graham N.A., Etherson M.L., Kennedy J., Fernandes A.C., et al. Fgf receptor 3 activation promotes selective growth and expansion of occipitotemporal cortex. Neural. Dev. 2009, 4:4.
35. Kang W., Wong L.C., Shi S.H., Hebert J.M. The transition from radial glial to intermediate progenitor cell is inhibited by FGF signaling during corticogenesis. J. Neurosci. 2009, 29:145711-145780.
36. Richtsmeier J.T., Flaherty K. Hand in glove: brain and skull in development and dysmorphogenesis. Acta Neuropathol. 2013, 125:469-489.
37. Ornitz D.M. FGFs heparan sulfate and FGFRs: complex interactions essential for development. Bioessays 2000, 22:108-112.
38. Ornitz D.M., Itoh N. Fibroblast growth factors. Genome Biol. 2001, 2:3005. reviews.
39. Reuss B., von Bohlen und Halbach O. Fibroblast growth factors and their receptors in the central nervous system. Cell Tissue Res. 2003, 313:139-157.
40. Kan M., Wang F., Xu J., Crabb J.W., Hou J., McKeehan W.L. An essential heparin-binding domain in the fibroblast growth factor receptor kinase. Science 1993, 259:1918-1921.
41. Gong S.G. Isoforms of receptors of fibroblast growth factors. J. Cell. Physiol. 2014, 229:1887-1895.
42. Lee M., Kang Y., Suk K., Schwab C., Yu S., McGeer P.L. Acidic fibroblast growth factor (FGF) potentiates glial-mediated neurotoxicity by activating FGFR2 IIIb protein. J. Biol. Chem. 2011, 286:41230-41245.
43. Paradiso B., Zucchini S., Simonato M. Implication of fibroblast growth factors in epileptogenesis-associated circuit rearrangements. Front. Cell Neurosci. 2013, 7:152.
44. Gomez-Pinilla F., van der Wal E.A., Cotman C.W. Possible coordinated gene expressions for FGF receptor FGF-5, and FGF-2 following seizures. Exp. Neurol. 1995, 133:164-174.
45. Cuevas P., Gimenez-Gallego G. Antiepileptic effects of acidic fibroblast growth factor examined in kainic acid-mediated seizures in the rat. Neurosci. Lett. 1996, 203:66-68.
46. Riva M.A., Gale K., Mocchetti I. Basic fibroblast growth factor mRNA increases in specific brain regions following convulsive seizures. Brain Res. Mol. Brain Res. 1992, 15:311-318.
47. Harirchian M.H., Tekieh A.H., Modabbernia A., Aghamollaii V., Tafakhori A., Ghaffarpour M., et al. Serum and CSF PDGF-AA and FGF-2 in relapsing-remitting multiple sclerosis: a case-control study. Eur. J. Neurol. 2012, 19:241-247.
48. Sarchielli P., Di Filippo M., Ercolani M.V., Chiasserini D., Mattioni A., Bonucci M., et al. Fibroblast growth factor-2 levels are elevated in the cerebrospinal fluid of multiple sclerosis patients. Neurosci. Lett. 2008, 435:223-228.
49. Clemente D., Ortega M.C., Arenzana F.J., de Castro F. FGF-2 and anosmin-1 are selectively expressed in different types of multiple sclerosis lesions. J. Neurosci. 2011, 31:14899-14909.
50. Furusho M., Dupree J.L., Nave K.A., Bansal R. Fibroblast growth factor receptor signaling in oligodendrocytes regulates myelin sheath thickness. J. Neurosci. 2012, 32:6631-6641.
51. Ruffini F., Furlan R., Poliani P.L., Brambilla E., Marconi P.C., Bergami A., et al. Fibroblast growth factor-II gene therapy reverts the clinical course and the pathological signs of chronic experimental autoimmune encephalomyelitis in C57BL/6 mice. Gene Ther. 2001, 8:1207-1213.
52. Zhou L., Lu G., Shen L., Wang L., Wang M. Serum levels of three angiogenic factors in systemic lupus erythematosus and their clinical significance. Biomed. Res. Int. 2014, 2014:627126.
53. Ichinose K., Arima K., Ushigusa T., Nishino A., Nakashima Y., Suzuki T., et al. Distinguishing the cerebrospinal fluid cytokine profile in neuropsychiatric systemic lupus erythematosus from other autoimmune neurological diseases. Clin. Immunol. 2015, 157:114-120.
54. Itoh N., Ohta H. Roles of FGF20 in dopaminergic neurons and Parkinson's disease. Front. Mol. Neurosci. 2013, 6:15.
55. Takagi Y., Takahashi J., Saiki H., Morizane A., Hayashi T., Kishi Y., et al. Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model. J. Clin. Invest. 2005, 115:102-109.
56. Sleeman I.J., Boshoff E.L., Duty S. Fibroblast growth factor-20 protects against dopamine neuron loss in vitro and provides functional protection in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Neuropharmacology 2012, 63:1268-1277.
57. van der Walt J.M., Noureddine M.A., Kittappa R., Hauser M.A., Scott W.K., McKay R., et al. Fibroblast growth factor 20 polymorphisms and haplotypes strongly influence risk of Parkinson disease. Am. J. Hum. Genet. 2004, 74:1121-1127.
58. Mizuta I., Tsunoda T., Satake W., Nakabayashi Y., Watanabe M., Takeda A., et al. Calbindin 1, fibroblast growth factor 20, and alpha-synuclein in sporadic Parkinson's disease. Hum. Genet. 2008, 124:89-94.
59. Xu X., Wang N., Xu H., Xie A., Jiang H., Xie J. Fibroblast growth factor 20 polymorphism in sporadic Parkinson's disease in Northern Han Chinese. J. Clin. Neurosci. 2013, 20:1588-1590.
60. Otto D., Unsicker K. Basic FGF reverses chemical and morphological deficits in the nigrostriatal system of MPTP-treated mice. J. Neurosci. 1990, 10:1912-1921.
61. Noda M., Takii K., Parajuli B., Kawanokuchi J., Sonobe Y., Takeuchi H., et al. FGF-2 released from degenerating neurons exerts microglial-induced neuroprotection via FGFR3-ERK signaling pathway. J. Neuroinflamm. 2014, 11:76.
62. Timmer M., Cesnulevicius K., Winkler C., Kolb J., Lipokatic-Takacs E., Jungnickel J., et al. Fibroblast growth factor (FGF)-2 and FGF receptor 3 are required for the development of the substantia nigra, and FGF-2 plays a crucial role for the rescue of dopaminergic neurons after 6-hydroxydopamine lesion. J. Neurosci. 2007, 27:459-471.
63. Klejbor I., Myers J.M., Hausknecht K., Corso T.D., Gambino A.S., Morys J., et al. Fibroblast growth factor receptor signaling affects development and function of dopamine neurons - inhibition results in a schizophrenia-like syndrome in transgenic mice. J. Neurochem. 2006, 97:1243-1258.
64. Kiyota T., Ingraham K.L., Jacobsen M.T., Xiong H., Ikezu T. FGF2 gene transfer restores hippocampal functions in mouse models of Alzheimer's disease and has therapeutic implications for neurocognitive disorders. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:E1339-E1348.
65. Woodbury M.E., Ikezu T. Fibroblast growth factor-2 signaling in neurogenesis and neurodegeneration. J. Neuroimmune Pharmacol. 2014, 9:92-101.
66. Katsouri L., Ashraf A., Birch A.M., Lee K.K., Mirzaei N., Sastre M. Systemic administration of fibroblast growth factor-2 (FGF2) reduces BACE1 expression and amyloid pathology in APP23 mice. Neurobiol. Aging 2015, 36:821-831.
67. Turner C.A., Watson S.J., Akil H. The fibroblast growth factor family: neuromodulation of affective behavior. Neuron 2012, 76:160-174.
68. Takebayashi M., Hashimoto R., Hisaoka K., Tsuchioka M., Kunugi H. Plasma levels of vascular endothelial growth factor and fibroblast growth factor 2 in patients with major depressive disorders. J. Neural Transm. 2010, 117:1119-1122.
69. He S., Zhang T., Hong B., Peng D., Su H., Lin Z., et al. Decreased serum fibroblast growth factor - 2 levels in pre- and post-treatment patients with major depressive disorder. Neurosci. Lett. 2014, 579:168-172.
70. Li J.Z., Bunney B.G., Meng F., Hagenauer M.H., Walsh D.M., Vawter M.P., et al. Circadian patterns of gene expression in the human brain and disruption in major depressive disorder. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:9950-9955.
71. Turner C.A., Gula E.L., Taylor L.P., Watson S.J., Akil H. Antidepressant-like effects of intracerebroventricular FGF2 in rats. Brain Res. 2008, 1224:63-68.
72. Jarosik J., Legutko B., Werner S., Unsicker K., von Bohlen Und Halbach O. Roles of exogenous and endogenous FGF-2 in animal models of depression. Restor. Neurol. Neurosci. 2011, 29:153-165.
73. Elsayed M., Banasr M., Duric V., Fournier N.M., Licznerski P., Duman R.S. Antidepressant effects of fibroblast growth factor-2 in behavioral and cellular models of depression. Biol. Psychiatry 2012, 72:258-265.
74. Ji X.W., Wu C.L., Wang X.C., Liu J., Bi J.Z., Wang D.Y. Monoamine neurotransmitters and fibroblast growth factor-2 in the brains of rats with post-stroke depression. Exp. Ther. Med. 2014, 8:159-164.
75. Perez J.A., Clinton S.M., Turner C.A., Watson S.J., Akil H. A new role for FGF2 as an endogenous inhibitor of anxiety. J. Neurosci. 2009, 29:6379-6387.
76. Turner C.A., Clinton S.M., Thompson R.C., Watson S.J., Akil H. Fibroblast growth factor-2 (FGF2) augmentation early in life alters hippocampal development and rescues the anxiety phenotype in vulnerable animals. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:8021-8025.
77. Xin F., Susiarjo M., Bartolomei M.S. Multigenerational and transgenerational effects of endocrine disrupting chemicals: a role for altered epigenetic regulation?. Semin. Cell Dev. Biol. 2015.
78. Chaudhury S., Aurbach E.L., Sharma V., Blandino P., Turner C.A., Watson S.J., et al. FGF2 is a target and a trigger of epigenetic mechanisms associated with differences in emotionality: partnership with H3K9me3. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:11834-11839.
79. Pan R.L., Xiang L.X., Wang P., Liu X.Y., Nie L., Huang W., et al. Low-molecular-weight fibroblast growth factor 2 attenuates hepatic fibrosis by epigenetic down-regulation of Delta-like1. Hepatology 2014, 61:1708-1720.
80. Mallei A., Shi B., Mocchetti I. Antidepressant treatments induce the expression of basic fibroblast growth factor in cortical and hippocampal neurons. Mol. Pharmacol. 2002, 61:1017-1024.
81. Kajitani N., Hisaoka-Nakashima K., Morioka N., Okada-Tsuchioka M., Kaneko M., Kasai M., et al. Antidepressant acts on astrocytes leading to an increase in the expression of neurotrophic/growth factors: differential regulation of FGF-2 by noradrenaline. PLoS ONE 2012, 7:e51197.
82. Wang T., Zeng Z., Hu Z., Zheng L., Li T., Li Y., et al. FGFR2 is associated with bipolar disorder: a large-scale case-control study of three psychiatric disorders in the Chinese Han population. World J. Biol. Psychiatry 2012, 13:599-604.
83. Liu X., Zhang T., He S., Hong B., Chen Z., Peng D., et al. Elevated serum levels of FGF-2 NGF and IGF-1 in patients with manic episode of bipolar disorder. Psychiatry Res. 2014, 218:54-60.
84. Kao C.Y., Hsu Y.C., Liu J.W., Lee D.C., Chung Y.F., Chiu I.M. The mood stabilizer valproate activates human FGF1 gene promoter through inhibiting HDAC and GSK-3 activities. J. Neurochem. 2013, 126:4-18.
85. Terwisscha van Scheltinga A.F., Bakker S.C., Kahn R.S., Kas M.J. Fibroblast growth factors in neurodevelopment and psychopathology. Neuroscientist 2013, 19:479-494.
86. O'Donovan M.C., Norton N., Williams H., Peirce T., Moskvina V., Nikolov I., et al. Analysis of 10 independent samples provides evidence for association between schizophrenia and a SNP flanking fibroblast growth factor receptor 2. Mol. Psychiatry 2009, 14:30-36.
87. Shi Y., Li Z., Xu Q., Wang T., Li T., Shen J., et al. Common variants on 8p12 and 1q24.2 confer risk of schizophrenia. Nat. Genet. 2011, 43:1224-1227.
88. Gaughran F., Payne J., Sedgwick P.M., Cotter D., Berry M. Hippocampal FGF-2 and FGFR1 mRNA expression in major depression, schizophrenia and bipolar disorder. Brain Res. Bull. 2006, 70:221-227.
89. Katsel P., Davis K.L., Gorman J.M., Haroutunian V. Variations in differential gene expression patterns across multiple brain regions in schizophrenia. Schizophr. Res. 2005, 77:241-252.
90. Hashimoto K., Shimizu E., Komatsu N., Nakazato M., Okamura N., Watanabe H., et al. Increased levels of serum basic fibroblast growth factor in schizophrenia. Psychiatry Res. 2003, 120:211-218.
91. Flajolet M., Wang Z., Futter M., Shen W., Nuangchamnong N., Bendor J., et al. FGF acts as a co-transmitter through adenosine A(2A) receptor to regulate synaptic plasticity. Nat. Neurosci. 2008, 11:1402-1409.
92. Herbert C., Lassalle G., Alcouffe C., Bono F. Approaches targeting the FGF-FGFR system: a review of the recent patent literature and associated advanced therapeutic agents. Pharm. Pat. Anal. 2014, 3:585-612.
93. Doherty P., Walsh F.S. CAM-FGF receptor interactions: a model for axonal growth. Mol. Cell. Neurosci. 1996, 8:99-111.
94. Polanska U.M., Fernig D.G., Kinnunen T. Extracellular interactome of the FGF receptor-ligand system: complexities and the relative simplicity of the worm. Dev. Dyn. 2009, 238:277-293.
95. Enevoldsen M.N., Kochoyan A., Jurgenson M., Jaako K., Dmytriyeva O., Walmod P.S., et al. Neuroprotective and memory enhancing properties of a dual agonist of the FGF receptor and NCAM. Neurobiol. Dis. 2012, 48:533-545.
96. Pankratova S., Bjornsdottir H., Christensen C., Zhang L., Li S., Dmytriyeva O., et al. Immunomodulator CD200 promotes neurotrophic activity by interacting with and activating the fibroblast growth factor receptor. Mol. Neurobiol. 2014.
97. Bojesen K.B., Clausen O., Rohde K., Christensen C., Zhang L., Li S., et al. Nectin-1 binds and signals through the fibroblast growth factor receptor. J. Biol. Chem. 2012, 287:37420-37433.